<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43608">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01997125</url>
  </required_header>
  <id_info>
    <org_study_id>Reanimation in Tetraplegia</org_study_id>
    <secondary_id>G130055</secondary_id>
    <nct_id>NCT01997125</nct_id>
  </id_info>
  <brief_title>Reanimation in Tetraplegia</brief_title>
  <official_title>Reanimation in Tetraplegia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ali Rezai, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to allow the investigation of the Neural Bridging
      System for participants with tetraplegia to assess if the investigational device can
      reanimate a paralyzed limb under voluntary control by the participant's thoughts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study plans to enroll participants who have been diagnosed with C4- C6 ASIA A spinal
      cord injuries (motor and sensory complete neurologic injuries), who are more than 1 year
      post injury, and who are neurologically stable.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Voluntary Movement</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome measure of this study is the achievement of voluntary movement of the upper extremity.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Spinal Cord Injury (Quadreplegia)</condition>
  <arm_group>
    <arm_group_label>Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neural bridge system implant and external stimulator</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neural Bridging System</intervention_name>
    <description>Implanted device</description>
    <arm_group_label>Open Label</arm_group_label>
    <other_name>Blackrock Microsystems Neuroport</other_name>
    <other_name>Neuromuscular Stimulator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be 21 years or older.

          -  Must be tetraplegic (C4- C6 ASIA A).

          -  12 months post injury and neurologically stable.

          -  Participant is willing to comply with all follow-up evaluations at the specified
             times.

          -  Participant is able to provide informed consent prior to enrollment in the study.

          -  The participant is fluent in English.

          -  Participant must have a caregiver willing to participate in the study who will
             provide care for the surgical site.

        Exclusion Criteria:

          -  No active wound healing or skin breakdown issues.

          -  No history of poorly controlled autonomic dysreflexia.

          -  Medical contraindications for general anesthesia, craniotomy, or surgery.

          -  Diagnosis of acute myocardial infarction or cardiac arrest within previous 6 months.

          -  Participants with any type of destruction and/or damage to the motor cortex region as
             determined by MRI.

          -  History of psychiatric disturbance or dementia

          -  Other implantable devices such as heart/brain pacemakers

          -  Participants who rely on ventilators

          -  Co-morbid conditions that would interfere with study activities or response to
             treatment.

          -  History of a neurological ablation procedure.

          -  Labeled contraindication for MRI.

          -  History of hemorrhagic stroke.

          -  History of HIV infection or ongoing chronic infection (such as tuberculosis).

          -  Pregnant or of child-bearing potential and are not taking acceptable methods of
             contraception.

          -  Participation in another FDA device or medication trial that would interfere with the
             current study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Rezai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Phuong Nguyen</last_name>
    <phone>614-366-6952</phone>
    <email>Phuong.Nguyen2@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center - Center for Neuromodulation</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phuong Nguyen</last_name>
      <phone>614-366-6952</phone>
      <email>Phuong.Nguyen2@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Mahler</last_name>
      <phone>614-366-6639</phone>
      <email>Kimberly.Mahler@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ali Rezai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 22, 2013</lastchanged_date>
  <firstreceived_date>November 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Ohio State University</investigator_affiliation>
    <investigator_full_name>Ali Rezai, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Quadriplegia</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
